1. Introduction {#s0005}
===============

Lung cancer is biggest incidences of cancers throughout the world amongst all the type of cancers. In spite of early identification, a proper treatment, non-small-cell lung cancer is commonly diagnosed at an advanced stage through 75.0--80.0% containing already specified metastases ([@b0085], [@b0270]). The prediction of diagnosis is very poor and the survival rate for 5-year is smaller than 15% ([@b0145]). A new chemical entity (NCE) and their formulation is urgently required for treatment of lung cancer. It has been reported that dietary optimization is among the most effective approaches for cancer prevention ([@b0250]). Importantly, about 20% of all cases of cancer are preventable by modified diet containing high amount and variety of vegetables and fruits ([@b0135]). Most of the natural compounds have highly contained polyphenolic phytochemicals in the fruits, vegetables, and cereal and involved in protecting plants from microbial infections, deterrence of herbivores, preventing reactive oxygen species (ROS) stress, regulation of growth processes, and ripening ([@b0250]). Polyphenol structure is characterized by the presence of multiphenol units, which might contribute to oxidative stability of plant tissue and other organoleptic characteristics, such as color, flavor, and odor ([@b0250]). Due to favorable safety profile and profound antioxidant activity, polyphenolic phytochemicals have been intensively studied as anticancer adjuvants ([@b0190], [@b0055], [@b0315]). Particularly, in mice‑harboring mammary carcinoma 4T1, green tea polyphenols dramatically suppressed cancer development and inhibited tumor metastasis ([@b0075]). Green tea contained flavonoid in the form of flavanols in which mostly present catechins ([@b0240], [@b0300]). Catechins showed antioxidants property that are highly useful to the human body ([@b0215], [@b0005]). All 6-catechins found in green tea (e.g. Catechin Hydrate) with great nutraceutical potential are water-soluble with colourless active entities which showed astringent and bitter taste to green tea infusion ([@b0005], [@b0330]). All catechins including Catechin Hydrate was already proved in treatment of various types of cancer like breast, colon, pancreatic, duodenum, skin, esophageal, lung, and prostate cancer ([@b0155], [@b0180], [@b0200], [@b0230], [@b0290], [@b0165], [@b0150], [@b0060], [@b0065], [@b0295], [@b0115], [@b0185]).

Now a drays, various research scientists are targeting the drugs via nose--to--lungs that showed different types of useful applications like avoid hepatic first pass metabolism and non-invasive route with easy to application of drugs ([@b0225], [@b0105], [@b0340], [@b0170]). Therefore, these PLGA-NPs. nanoparticles can be a better approach in the comparison of others. PLGANPs are known to be biodegradable, biocompatible and non-toxic and have been used for biomedical application for more than two decades. PLGA has been widely investigated for formulation of NP because of its biocompatibility, safety, ability to promote mucoadhesion and enhanced drug stability via intranasal drug delivery as compared to other routes of drug administration ([@b0045], [@b0050]). PVA-NPs (polyvinyl alcohol-NPs) are also used similarly because of the maximum permeability, better solubility, and increase compatibility of mixtures with excellent rheological properties on the various shapes and flexibility through many types of drug delivery ([@b0045], [@b0050]). Before designing the intranasal preparations, everyone must think the problem of little staying time of drug in the nasal cavity. This is very important for any type of optimized-formulation that should contain a highly mucoadhesive with the maximum nasal residence time. If we are going to administer any drug-formulation intranasally that it should contain a mucoadhesive property followed by enhancement of absorption of CTH-drug. Though, that dosage form should be useful to enhance the nasal retention time. Now a days, an attractive tool comes into the market i.e. nasal gel (*in situ*) formulations showed biocompatible and biodegradable-nanoparticles as a controlled release of drug like CTH ([@b0015], [@b0125], [@b0205], [@b0040], [@b0050]). A great attention have been developed now a days about the polymeric-NPs that showed longer therapeutic action, control rate of drug release with maximum drug-loading (DL), increasing their surface area. Thus, the release of drug will fast initially followed by maintaining the drug therapeutic level as compare with other carriers and drug-delivery for the targeted to particular sites of the body. These polymeric nanoparticles provide the some other additional useful applications as compared to other drugs-formulations delivered through nose--to--lungs because these- nanoparticles protect the drugs via encapsulation stay away from the direct participation of biological degradation to increase the bioavailability of drugs into the lungs.

Likewise, literature survey ([@b0160], [@b0285], [@b0305], [@b0310], [@b0110], [@b0265], [@b0095], [@b0245]) reports different methods for green tea or tea or coffee extracts, fruits juices, and other plants extracts for analysis of samples. However, they published concurrent development with various catechins at the similar time, i.e. plasma analysis is any reports not available for Catechin Hydrate alone. There are two methods developed for catechins for the analysis of brain and urine samples ([@b0195], [@b0005]). Besides this, it is very important for current study is lack of availability of any method for lungs as well as plasma bioanalysis of single-CTH-only with very lesser time upto picogram level. In the current study, a novel bioanalytical UPHPL-MS method was successfully developed, validated, and applied for all pulmokinetics parameters evaluations of CS--coated--PLGA--NPs by UHPLC-ESI-triple-quadrupole-MS/MS. The current study showed a bioanalytical method contained various applications in terms of higher sensitivity, highest efficiency, and very low retention with very less total run time for the estimation of pulmokinetics parameters in lungs as well as plasma.

This is a first time development of novel chitosan (CS)--coated--PLGA--NPs to increased lungs targeting of CTH. The major objective is to improve the bioavailability of CTH in the lungs after the i.n. delivery of optimized-CS-CTH-PLGA-NPs to achieve an improved CTH-therapeutic level in the lungs. It was also avoided the unrequested systemic exposure of CTH alongwith required optimum dose for therapeutic-level of lungs. CS-CTH-PLGA--NPs were showed excellent effective-solubility and their permeability. Optimized-CS-CTH-PLGA-NPs were characterized by many physicochemical parameters to estimate their suitable CTH-delivery of nose-to-lungs. A comparative pulmokinetics study was performed via delivery of CS-CTH-PLGA-NPs from different routes (i.v., oral, and i.n.) in wistar rats. The quantification of CAT in lungs was carried out via a newly developed bioanalytical UHPLC-MS/MS method in the lungs for the treatment of lungs cancer by cancer cell lines. Further evaluation of the formulated NPs was performed on human non-small cell lung carcinoma (NSCLC) H1299-cell-lines to evaluate cytotoxicity, apoptotic potential and to evaluate the cell cycle arrest potential. Finally, the toxicity study was successfully established which is an important parameter for the safety of newly developed-NPs.

2. Materials and methodology {#s0010}
============================

We have bought 99.98% purity CTH from AK Scientific, Inc. 30,023 Ahern Avenue Union City, CA 94587, USA. CS, PVA (MW 25000), and PLGA from Tokyo Chemical Industry Co., Ltd. 6-15-9 Toshima, Kita-ku, Tokyo 114-0003 and Polysciences Inc, 400 Valley Road were bought. DCM was bought from Sigma‑Aldrich Corporation (St. Louis, MO, USA). All the analytical solvents were bought from Sigma-Aldrich. The whole analysis was performed with the help of Milli‑Q‑Water. The apoptosis detection kit was bought from BD Bioscience.

2.1. Development of NPs {#s0015}
-----------------------

For the preparation of PLGA NPs, we slightly modified Ahmad et al method based on double emulsification (w/o/w) solvent evaporation method ([@b0040], [@b0005]). CTH was solubilized in PVA solution (1.10%w/v) to prepare an aqueous as a internal phase (IAP). PLGA was solubilized in DCM to form organic phase. Probe sonicator (Ultrasonic processor, Sonopuls, Bandelin, Germany) was used to emulsified IAP in the organic phase for 4.0 min at voltage efficiency (60.0%) wit temperature (25.0 ± 1.0 °C) to prepare w/o as a primary emulsion (PE). PE has been additionally emulsified through sonication by various PVA concentration solution or EAP (external aqueous phase) to obtain a 2°-emulsion (w/o/w). For the evaporation of organic solvent, 2°-emulsion was kept on magnetic stirrer upto 4 to 5 h. NPs were found in the form of suspension, it was centrifuged at 15000.0 rpm (30.0 min) followed by rising for three-times for the removal of extra amount of PVA as well as CTH sticked on the NPs-surface. Opt-NPs were washed pellets and dispersed in the 5.0%w/v mannitol solution followed by dried with help of freeze dryer (Lab Conco., LPYH, Lock 6, USA freeze dryer) at −60.0 °C (upto 24.0 h) to get freeze-dried-NPs.

A specific amount of CTH-PLGA-NPs suspensions is incubated CS-volume (2.0 mg/ml) in 0.50% acetic solution for 2.0 h at room temperature ([@b0040], [@b0005]). Obtained-CS-CTH-PLGA-NPs were centrifuged followed by two times washing and after that redispersed in the Milli-Q-water (predetermined volume). Resulted-NPs were dispersed and stabilized with the help of Lyophilizer (Lab Conco., LPYH, Lock 6, USA freeze dryer) for 3.0 days (at −60.0 °C). Resulted CS-CTH-PLGA-NPs were formulated in triplicate.

2.2. Characterizations of CS/CTH-PLGA-NPs {#s0020}
-----------------------------------------

### 2.2.1. PDI, ZP, and particle size {#s0025}

Particle size determination is the very essential parameter. If particle size decreases parallely increases the surface area for the absorption of drug ([@b0040], [@b0005]). PDI, particle size, and ZP for the opt-nanoformulation were examined through Dynamic light scattering technique (Malvern--Zetasizer, Nano--Zetasizer, UK). Dilution is very important to before analyze the particle size. At the time of particle size analysis, we have maintained the temperature 25.0 °C and 90° fixed the scattering angle ([@b0040], [@b0005]). The samples were diluted to used and analyse size and surface charge of nanoformulations, where each measurements were prepared in triplicate. At the time of particle size analysis and their surface charge for NPs, we determined the samples in triplicate.

### 2.2.2. SEM (Scanning electron microscopy) {#s0030}

We adopted to use Ahmad et al method to examine the shape of particles via SEM (FEI, INSPECT S50, Czech Republic) ([@b0040], [@b0005]).

### 2.2.3. TEM (transmission electron microscopy) {#s0035}

We adopted to use Ahmad et al method to examine the size of particles via TEM (FEI, MORGAGNE.68, Czech Republic) ([@b0040], [@b0005]).

### 2.2.4. EE (%Entrapment Efficiency), LC (%Loading Capacity), and Process Yield (%) {#s0040}

LC and EE of NPs were estimated through the ultracentrifugation for 30.0 min at 15,000 rpm at 4.0 °C. Our in house-developed UHPLC--MS/MS method helped to determine the CTH-free amount from supernatant ([@b0040], [@b0005]). EE and LC calculated on the basis of mentioned below equation for opt-NPs ([@b0040], [@b0005]):$$\text{EE}\left( \% \right) = \frac{\text{Whole}\,\text{CTH}\,\text{Quantity} - \text{Free}\,\text{CTH}\,\text{Amount}}{\text{Whole}\,\text{CTH}\,\text{Quantity}} \times 100$$$$\text{LC}\left( \% \right) = \frac{\text{Whole}\,\text{CTH}\,\text{Quantity} - \text{CTH}\,\text{Free}\,\text{Amount}}{\text{NPs}\,\text{Weight}} \times 100$$

Process Yield (%) was calculated through mentioned below formula:$$\text{Process}\,\text{Yield}\;\left( \% \right) = \frac{\text{W}_{1}\left( {\text{Dried}\,\text{NPs}\,\text{Weight}} \right)}{\text{W}_{2}\left( {\text{overall}\,\text{weight}\,\text{of}\,\text{dried}\,\text{initial}\,\text{material}} \right)}\; \times 100$$

2.3. Differential Scanning calorimetry (DSC) study {#s0045}
--------------------------------------------------

CTH (Pure Catechin), PLGA, PVA (Poly Vinyl Alcohol), CTH, PLGA, PVA-physical mixture, lyophilized CTH-PLGA-NPs, Pure CS, and CS-CTH-PLGA-NPs samples were analysed by DSC 214 Polyma (NETZSCH‑Wittelsbacherstraße 42, 95,100 Selb, Germany). 10.0 mg of every sample was taken inside pan which was made up of aluminium and then crimped after that 20.0--400.0 °C heated with 10.0 °K/min rate with N~2~ gas continuously-supplied ([@b0040], [@b0005]).

2.4. *In vitro* drug release {#s0050}
----------------------------

The *in vitro* release of CTH from the CTH-PLGA-NPs & CS-PLGA-NPs were carried out in two separate release-medium with pH 7.40 and pH 5.50 in order to initiate the physiologic and acidic condition of cancer cells with slight modification ([@b0010], [@b0030], [@b0035]). Equal quantities of CTH-PLGA NP samples were packed in a dialysis sac and suspended in a 25.0 ml of the respective release medium having different pH 5.50 and pH 7.40. A similar set of release study of the CS coated CTH-PLGA NP samples were continued. In both the cases, temperature was maintained at 37 °C in a paddle type dissolution apparatus where the speed of paddle was set to 100 rpm. At a particular interval of time, 1.0 ml sample aliquots were collected and replaced with equal volume of fresh buffer. 1.0 ml every test sample was withdrawn from each sampling-time point. After the withdrawal of every test sample, it was filtered through 0.20 μm syringe-filter and then analysed by UHPLC--MS/MS-method ([@b0010], [@b0030], [@b0035]).

2.5. E*x-vivo* study based on nasal mucosa based permeation {#s0055}
-----------------------------------------------------------

Local slaughterhouse has provided the fresh nasal tissues from the goat's nasal cavities. A fix area i.e. 0.785 cm^2^ for tissue cells was taken for the permeation of CTH (Logan Instrument Corporation, Piscataway, NJ). A saline 20.0 ml phosphate buffer (pH: 7.40, at 37.0 °C) was taken into the receptor chamber as in a each and every separate pure-CTH-suspension, lyophilized-CTH-PLGA-NPs and lyophilized-CS-CTH-PLGA-NPs (∼CTH: 10.0 mg) were taken in the donor chamber (21.50--2.0 ml) after pre-incubation-time for 20.0 min in each analysis. 500.0 µl samples were withdrawn from receptor chamber based on predetermined time intervals. All the samples filtered through 0.20 μm syringe-filter and then analysed by UHPLC-MS/MS-method ([@b0020]).

2.6. Cytotoxicity of free CAT and CS-CAT-PLGA NPs {#s0060}
-------------------------------------------------

Prediction of cytotoxicity of investigational agents in different cells is among the first *in vitro* bioassay techniques, which usually provides the basis of crucial means of screening and safety assessment of the investigational agent ([@b0320]). Therefore, the MTT colorimetric assay was conducted in NSCLC cell line (H1299) with free CAT, CS-CAT-PLGA NPs and placebo CS-PLGA NPs. The specific number of H1299 cells (6 × 10^3^ cells) were seeded in each well of the 96-well plate for a period of 24 h. The incubated cells were then treated with various concentrations (5--100.0 μg ml^−1^) of free CAT, CS-CAT-PLGA-NPs and placebo CS-PLGA-NPs. Following an incubation period of 24.0 h the treated samples were removed from the wells and the cells were incubated with 25.0 μl of MTT solution (0.50%, w/v) for 4.0 h at 37.0 °C. Later after incubation, the unreacted MTT solution was removed and the cells were exposed to 150 μl DMSO in each well for a period of 20.0 min to solubilise the formed formazan crystals. At last, the absorbance of the formazan solution in each well was examined at 570.0 nm via microplate reader (Thermo Fisher Scientific, Waltham, MA), which was proportionate with the number of viable cells in the wells. Viability of the treated cells was calculated comparing with control cells and reported.

2.7. Induction of apoptosis in H1299 cells by free CAT and CS-CAT-PLGA-NPs {#s0065}
--------------------------------------------------------------------------

The technique (Double staining) was used to analyse apoptotic potential of the free CAT and formulated NPs. In due course, the H1299 cells were seeded in 6-well plates where the cells are incubated with free CAT and CS-CAT-PLGA-NPs. Following an incubation of 24.0 h, cells washing were performed two times with cold phosphate buffer saline. The cells are then re-suspended in binding buffer and treated with 5.0 μl of Annexin V--fluorescein isothiocyanate (FITC) conjugate and 5.0 μl propidium-iodide. The cells were stained following an incubation of 15.0-min in dark at room temperature. The cells were then analysed through flow cytometry (BD FACS AriaTm III) and obtained data were evaluated via FACS DIVA 8.0.2.

2.8. Western blotting {#s0070}
---------------------

CAT and CS-CAT-PLGA-NPs effect was evaluated by the Bax and Bcl-2 apoptotic expression markers with the help of analysis of western blot in the lung cancer (H1299) cells. CAT and CS-CAT-PLGA-NPs incubated with H1299 cells were seeded in six-well plates. PBS was used to wash all the cells and radio-immuno-precipitation assay lysis buffer (RIPA buffer) was used for incubation for thirty minutes on the ice. The supernatant liquid samples were collected after 12,000.0 rpm centrifugation at 4.0 °C that contained the proteins. SDS-PAGE was used to separate out the all extracted proteins and then it transferred to PVDF membranes. 5.0% BSA and TBST were used to keep the membrane for 2.0 hrs at room temperature to obstruct every binding site on the membrane. Primary antibodies to β-actin, BAX and Bcl-2 were use to incubate the membrane. The membrane was incubated after 10.0 h with horseradish peroxidase-conjugated secondary antibodies for 1.0 h. Chemiluminescence reagent kit was used to identify the signal and imagined protein bands quantification was carried out through densitometric analysis with the help of image J software.

2.9. CAT and CS-CAT-PLGA-NPs induced cell cycle analysis {#s0075}
--------------------------------------------------------

H1299 cells were used to verify the effect of free CAT and formulated NPs on the cell cycle distribution ([@b0220]). The cells were incubated in 96-well plate with a fixed concentration of CAT in different formulation. Then the cells were harvested and were fixed with 75% ethanol at 4.0 °C for 30 min. The cells were washed again with phosphate buffer saline twice and re-suspended in 50 mg/mL propidium iodide solution containing 50 ng/mL of RNase for 30 min in the dark at room temperature. The number of cells was tested subsequently with the help of flow cytometer (BD FACS AriaTm III). Ten thousands cells data were collected from every data file in which were acquired data were analysed with the help of FACS DIVA 8.0.2 software.

2.10. Animal study {#s0080}
------------------

For the pulmokinetics study, we have taken the ethical approval from Imam Abdulrahman Bin Faisal University Ethical Committee (ethical approval number IRB-UGS-2019--05). Each cage has 4--5-rats (weight; 200--250 g). We have maintained natural light with dark cycle followed by the easy way to reachable food & water and also maintained the temperature 20--30 °C with 50--55% humidity.

2.11. UHPLC-MS/MS bioanalytical method development and their validation (MDMV) {#s0085}
------------------------------------------------------------------------------

US--FDA, 2001 guidelines were followed for MDMV for CTH. Eight different standard points were selected to plot CC (calibration curve) for linearity with the calculation of peak area ratio; 1/x^2^ regression was employed. Signal to noise was used 10:1 to measure lower limit of quantification (LLOQ) and LOD (Lower limit of Detection). We have withdrawn 6-pre-spiked of extracted samples to analyse by mean area response vs. post-extraction spiked CTH-free in the matrix (lungs and plasma). Same way, we determined recovery of IS samples. We analysed inter and intra-day accuracy and precision through the selection of LLOQQC, LQC, MQC, and HQC (for each QCs: 6-replicates) with one CC of lungs homogenate and plasma samples.

2.12. Required conditions for UHPLC-MS/MS {#s0090}
-----------------------------------------

UHPLC--MS/MS exhibited a binary solvent manager with autosampler was used that contain high resolution and very sensitive tunable mass detector (LCMS-8050, ESI, Triple Quadrupole, Japan). Pinnacle DB C18 (1.9 µm; 50.0 × 30.0 mm) column was used with a mobile phase (Acetonitrile: Water::91:09), 2.0 µl injection volume, with a flow rate (0.400 ml min^−1^) and total run time was 1.5 min. LCMS-8050 was used to determine the mass of the samples with the application of collision gas (Argon gas), scan time (1.0 min), inter-scan delay (0.020 sec with 0.10 µ scan step: 30,000.0 micro sec^−1^). Collision energy (25.0 eV CE for CTH and 21.5 eV for Quercetin) were selected for the quantification of CTH & IS in the negative ion mode. The *m*/*z* 289.21/109.21 and 301.21/151.21 transitions were used to bioanalysis of samples for CTH and Quercetin (IS), respectively. Lab Solution Software (V5.93) was used to calculate the exact mass determination with the amount of analyte as well as assessment of parent and daughter ions.

2.13. CC and QC samples preparation {#s0095}
-----------------------------------

CTH stock solution was prepared first in the methanol (10.0 mg 10.0 ml^−1).^ The various 8-CC concentrations were prepared like analyte (2.0% aqueous) in the blank matrix (plasma or lungs homogenate) of the rats that means matrix (980.0 ml blank) + analyte (20.0 ml of aqueous). CC-range (1.0--1000.0 ng ml^−1^) for CTH was prepared in different sampling matrixes points like 1, 2, 22, 208, 420, 638, 850, and 1000 ng ml^−1^. In a same way, all the QCs HQC (805.00), MQC (420.00), LQC (2.91), LLOQC (1.010), and IS (50 ng ml^−1^) were prepared water: methanol (1:1) mixture. The temperature (2--8 °C) stored all spiked freshly diluted.

2.14. Different types of matrix samples extraction {#s0100}
--------------------------------------------------

Lungs homogenate or plasma unknown samples with fresh known samples (CC and QC) were prepared and collected for bioanalysis. Each aliquot (550.0 μl) has taken in a fresh cleaned glass tube after that added IS (50.0 ng mL^−1^; 100.0 μl). After that, formic acid (200.0 μl; 5%) was added with vortexed (300 rpm) for 5--6 min to break the matrix protein. The samples was centrifuged at 4000 rpm (for 10 min at 4 °C) followed by transferred supernatant sample (4 ml) in a clean glass tube. All these samples were evaporated on water-bath (37 ± 1 °C) with the help of samples dried under nitrogen stream. We have reconstituted residues by mobile phase (700.0 μl) in order to vortexed (300 rpm) for 5 min. UHPLC vials were used to transfer the reconstituted residues for bioanalysis.

2.15. Pulmonokinetics {#s0105}
---------------------

In this study, optimized-CS-CAT-PLGA-NPs have used for their comparative pharmacokinetics study via delivery of CS-CAT-PLGA-NPs from different routes (i.v., oral, and intranasal) in wistar rats. On the basis of results, we are able to know the best route for lungs targeting drug delivery. For pulmonokinetics and actual reached CAT of CS-CAT-PLGA-NPs, rats were divided into three groups (6x3 = 18). The study was carried out at seven pre-selected time points of 0.25, 0.50, 1, 2, 4, 8, 12 and 24 hrs. Eighty one wistar rats in three groups (27 × 3 = 81) were randomly distributed as; Group-I: i.v., Group-II: oral, Group-III: intranasal. For bioanalytical determination of CAT in lungs and plasma, three animals at each time point were sacrificed to obtain plasma and lung homogenate.

2.16. *In vivo* Histopathological examination of CS-CAT-PLGA-NPs toxicity {#s0110}
-------------------------------------------------------------------------

Wistar rats were selected for CS-CAT-PLGA-NPs toxicity evaluation as this animal model offered a large surface area for intranasal to lungs of CS-CAT-PLGA-NPs and to accurately determine the CS-CAT-PLGA-NPs toxicity on the lungs as per the method reported by [@b0080], [@b0210]. All rats were sacrificed and then removed the lungs intact extraction after 7-days treatment. It was inflated through 4.0% paraformaldehyde tracheal instillation at 25.0 cm water airway pressure. The paraffin was used to embed the tissues and then sectioned. All the tissues stained with hematoxylin and eosin stain.

2.17. Evaluation based statistics {#s0115}
---------------------------------

All the data was analysed like mean ± SD (standard deviation). For data comparison ANOVA with *p* \< 0.05 was applied as a statistical tool. The software used for analysis was GraphPad v 3.0 (San Diego, CA).

3. Result and discussion {#s0120}
========================

3.1. Nanoformulation development and their characterizations {#s0125}
------------------------------------------------------------

PLGA NPs were prepared using PLGA and PVA through double emulsification-solvent evaporation method, where PVA acts as stabilizer of the formulation. Here, the particles size was reduced by ultrasonication techniques at nano-range followed by lower PDI. PLGA-NPs showed the particle size range 119.34 ± 11.61 nm in which DL didn't exhibited any significant enhance the NPs sizes. A significant enhance in particles size were determined 150.81 ± 15.91 nm while the PLGA-NPs were coated with CS ([Table 1](#t0005){ref-type="table"}). Incorporation of CAT within the nanostructure has shown to increase the PDI of the formulation significantly, however, in all the cases of the formulated particles were identified with \<0.310 PDI, representing monodisperse nature of the particles. As depicted in [Fig. 1](#f0005){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}, the surface charge of the opt-PLGA NPs were determined almost constant, slightly negative or near to the neutral (e.g., −4.10 ± 0.20 mV for CAT-PLGA-NPs). Comparatively after the nanoparticles coating, it was observed a significant change on the surface of NPs i.e. positive 26.01 ± 1.19 mV (for CS-CTH-PLGA NPs). It was also enhanced the stability of the NPs ([Fig. 1](#f0005){ref-type="fig"}B). CS have amino groups that is helpful to the enhanced the +ve ZP, it recommended that the CTH-PLGA NPs were satisfactorily coated through CS. CS-CTH-PLGA NPs contained +ve charge on their surface that enhances the adhesion and retention via cancer cells that are --vely charged membranes ([Fig. 2](#f0010){ref-type="fig"}) ([@b0335]). CS coated NPs decreases chances of NPs interactions with phagocytes and their absorption via these cells for the reason that +vely charged NPs are a very smaller absorption ([@b0260]). TEM and SEM micro-images showed the smooth surface and spherical CS-CTH-PLGA NPs ([Fig. 3](#f0015){ref-type="fig"}). EE of CAT within the PLGA nanocarrier was calculated as percentage ratio using the equation provided in the methodology section. With the change in concentration of PLGA, the %EE of CAT was varied proportionately within the PLGA-NPs, however, optimized formulation of CS coated CAT-PLGA-NPs were found to encapsulate 76.48 ± 4.51% with 8.76 ± 1.31 %DL. CS was coated on opt-CAT-PLGA-NPs that enhances the mucoadhesive and retention time in the nasal region. After that; we have our main objective i.e. opt-CS-CAT-PLGA-NPs were examined by *in-vitro* CTH-release, *ex vivo* permeation, H1299 cells cell lines, and their pulmokinetics study. Based on our findings, opt-CS-CAT-PLGA-NPs have been fruitfully coated on CTH-PLGA-NPs for the delivery of CAT via intranasal route. At last our conclusion is CTH adsorbed on the surface of opt-NPs due to CS (+vely charged) and CTH (−vely charged --OH hydroxyl ion) electrostatic interaction ([@b0040], [@b0010]). 26.01 ± 1.19 mV ZP showed the stability of opt-CS-CTH-PLGA NPs ([Fig. 1](#f0005){ref-type="fig"}B). Positive-charge on the surface of opt-CS-CTH-PLGA NPs facilitates to enhanced mucoadhesion with increment of residence time and decreases the mucociliary clearance of opt-CS-CTH-PLGA NPs from the nasal mucosa ([@b0205], [@b0040]).Table 1Average particle size, polydispersity index (PDI) zeta potential, %entrapment efficiency, %drug loading, %Yield of optimized formulations.Formulations TypeAverage PS (nm) ± SDAverage PDI ± SDAverage ZP (mV) ± SDAverage Yield (%) ± SDAverage EE (%) ± SDAverage DL (%) ± SDPLGA NPs119.34 ± 11.610.116 ± 0.05--3.94 ± 0.19------CTH-PLGA NPs124.64 ± 12.090.163 ± 0.03--4.10 ± 0.2091.65 ± 4.0172.34 ± 2.685.53 ± 0.16CS-PLGA NPs146.69 ± 15.680.291 ± 0.0227.51 ± 1.31------CS-CTH-PLGA NPs150.81 ± 15.910.306 ± 0.0326.01 ± 1.1995.48 ± 4.5776.48 ± 4.518.76 ± 1.31[^1]Fig. 1Zeta potential of PLGA NPs suspended in PBS (pH = 7.4), \[**A\]:** CTH-PLGA-NPs; \[**B\]:** CS-coated-CTH-PLGA-NPs.Fig. 2Schematic presentation of chitosan-coated PLGA NPs and their interaction with cancer cells. The positive surface of nanoparticles promotes adhesion and retention by cancer cells, which have negatively charged membranes.Fig. 3Scanning electron microscopy (SEM) **\[A\]** and transmission electron microscopy (TEM) \[**B\]** images of CS-coated-CH-loaded-PLGA-NPs.

PLGA polymer was used to prepare our CAT based nanoformulation in which for the stabilization, PVA was integrated. Generally for the formulation of PLGA-NPs, stabilizer was used i.e. PVA that is easily binds to PLGA with the help of PLGA interpenetration and PVA molecules at the time of preparation of nanoparticles ([@b0040], [@b0005]). PVA was used as a copolymer that exhibited polyvinyl alcohol & polyvinyl acetate by distinctive block copolymer in which vinyl part represents lipophilic property. PVA (lipophilic segment) is recognized and used as a penetrating agent for organic phase at the time preparation of NPs whereas from polymeric matrix used as elimination of organic solvent and it was finally resulted that PVA was entrapped inside the PLGA-matrix ([@b0280]). The decrement of particle size was due to the use of ultrasonication technique in the dispersed phase where these NPs as a nanocarrier showed a uniform characteristics nature in the size-range of 119.34 ± 11.61 nm. Ahmad et al reported before content selection of polymer, copolymer, and selected-drug at the time of preparation of NPs and the loading of drug inside the PLGA NPs followed by a required nanoparticles size range ([@b0040], [@b0005]). A smallest PDI was observed for our opt-CS-CTH-PLGA NPs which showed very small differences in all the batches at the time of nanoformulation development. Although loading of drug within the NP formulation showed to increase the PDI significantly, the value did not exceed 0.306, indicating formation of unimodal particles ([@b0090]). CS-coating on the PLGA-NPs represented a significant (*p* \< 0.05) enhance in particles size. On the other hand this change in particle-size did not affect the mean PDI as compared with uncoated particles. Finally, it was designated no agglomeration of the particles after coating with the CS.

3.2. Differential scanning calorimetry (DSC) {#s0130}
--------------------------------------------

CTH, PLGA, PVA, CTH + PVA + PLGA physical mixture, opt-CTH-PLGA NPs dried from lyophilizer, CS pure and opt-CS-CTH-PLGA NPs of DSC thermograms were displayed in [Fig. 4](#f0020){ref-type="fig"}. There are two major peaks i.e. one in-between 90 and 110 °C related to loss of water and other peak at 170.3 °C which is related to anhydrous CTH and also it showed mp i.e. very closed to reported mp 175 °C. Finally, it was decomposed \>200 °C. In the same way, CTH + PVA + PLGA physical mixture showed all the characteristic peaks. There was no peak in CTH-PLGA-NPs. It represents CTH entirely entrapped inside CTH-PLGA-NPs. A very distinctive peak was observed in-between 45.0 and 55.0 °C in PLGA pure polymer and also opt-PLGA NPs ([Fig. 4](#f0020){ref-type="fig"}) ([@b0040], [@b0010]). One exothermic broad peak was shown at 310.7 °C for CS but other peaks were endothermic i.e. 160.2 °C & 193.8 °C. It was shown again in opt-CS-CTH-PLGA NPs at 310.8 °C. In [Fig. 4](#f0020){ref-type="fig"}, CS-CTH-PLGA NPs showed again CS peak due to CS coated on CAT-PLGA-NPs. One more a very small peak of PLGA has been distinguished at 52.6 °C that could be lesser % of chitosan quantity compare to % of PLGA other side CTH-peak was not observed in the opt-CS-CTH-PLGA ([Fig. 4](#f0020){ref-type="fig"}) ([@b0040], [@b0010]).Fig. 4The DSC thermograms of Pure--Catechin (CTH), Polymer (PLGA), Poly Vinyl Alcohol (PVA), Physical Mixture of CTH, PVA, with PLGA, freeze--dried--CTH--loaded--optimized Polymeric (PLGA)--NPs, Pure Chitosan, and CS-Coated- CTH--loaded--optimized Polymeric PLGA--NPs.

3.3. *In vitro* CTH release evaluation {#s0135}
--------------------------------------

Any drug release from NPs delivery is very important to create intended physiological response that should be successfully changed via modification of physicochemical medium characteristics. CS coated CAT-PLGA is applied to transport the entrapped CAT within the cancer microenvironment, nanoformulations release study was evaluated at 2-different pH: 5.50 and 7.40, which roughly corresponds to the pH of the tumor microenvironment, different cellular compartments, and also for nasal mucosa respectively. CAT-release profiles from the NPs at various pH values were displayed in [Fig. 5](#f0025){ref-type="fig"}A, where it is clearly be demonstrated that the release of CAT from the PLGA NPs and CS-PLGA NPs were 67.01% and 80.93 ± 5.64% respectively at pH 7.4. The PLGA NPs showed burst release of 26.01% at 2.0 h whereas CS coated PLGA NPs showed 41.06 ± 2.98% drug releases. This result demonstrate that initial release of CAT in CS coated PLGA NPs was significantly greater than that in PLGA NPs and showed more sustain release at pH 7.4. At pH 5.5 the release rate of CAT in CS-coated PLGA NPs was very fast and CAT was released at 2.0 h whereas only 23.14 ± 1.51% drug release for PLGA NPs. This result indicating that CS coated PLGA NPs had pH-responsive properties. The release CAT from the PLGA-NPs was found to be sustained over a period of 24.0 h, with a cumulative release of 78.02 ± 4.41% at pH 5.5 in [Fig. 5](#f0025){ref-type="fig"}B.Fig. 5**\[A\]***In vitro* release profile of CTH-S, CTH--loaded--PLGA--NPs and Chitosan-coated-CTH--loaded--PLGA--NPs performed by using dialysis bag method, revealing sustained release pattern of CTH--loaded--PLGA--NPs and Chitosan-coated- CTH--loaded--PLGA--NPs (Temp was set at 37 °C, mean ± SD, n = 3) at pH 7.4 **\[A\]** and at pH 5.5 **\[B\]**.

It is important to bring into discussion that the surface charge and size of the nanocarriers are believed as most important determinants for improved permeability and retention (EPR) effect, where the size of the particle facilitate prolong retention within the systemic circulation escaping the reticuloendothelial cells, whereas charge of the particle facilitate to target to particular site and release the drug ([@b0100]). Therefore, the nanometric size of the current nanoformulations will facilitate prolong systemic circulation; thereby assist in passive targeting of the entrapped drug to the porous tumor area ([@b0140]). Further, it has also been revealed that the surface of the tumor cells are translocated with a negatively charged residue, phosphatidyl choline ([@b0255]), which facilitate binding of positively charged particles. The charge of the CAT-PLGA NPs was slightly negative in nature due to the presence of ionized carboxylic groups. Amphiphilic PVA presence forms a stable fence on the polymer surface, however, this fence of PVA shield the surface charge of the NPs and transfers the shear plane outer to the particle surface. Consequence of which, the surface charge of the NPs were recorded in slight negative zeta potential ([@b0280]). On the other hand, CS, the weak base polysaccharide, consists of β(1,4) linked monomers of N-acetyl-D-glucosamine and D-glucosamine, in which the surface amino groups are ionized in acidic environment to provide positive charge ([@b0235]). Therefore, the presence of positively charged amino groups on CS alters the ultimate surface charge of the CS coated NPs to positive. This shifting in surface charge upon CS coating on the PLGA NPs is clearly reflected in [Fig. 1](#f0005){ref-type="fig"}. Thus, positive charges of the CS-coated CAT-PLGA NPs is thought to potentiate binding of the nanocarriers to the surface of the negatively charged tumor cells during prolong circulation of the NPs within the circulation due to EPR effect.

Further, modulation of release of the entrapped drug in any carrier is utmost important to avoid unfavorable side effects due to exposure of the normal cells to the released drug. Therefore, current formulation approach is planned to modulate the release of entrapped drug (CAT) within the cancer microenvironment. To accomplish this goal, we have coated the CAT-PLGA NPs with CS, which will primarily release the drug at a particular pH of the cancerous environment. It is relevant to mention that the pH of the cancer microenvironment is acidic and ranges from 5.5 to 7.0, due to hypoxic condition during uncontrolled proliferation, deficient blood perfusion and glycolytic cancer cell metabolism ([@b0175]). Therefore, to ensure the release of the entrapped drug within the acidic environment and decreased systemic exposure of the drug, we have evaluated the release study in two different pH, 5.5 and 7.4, which roughly corresponds to the cancer environment and systemic circulation. The demonstrated result reflects release of the formulation from the CS coated CAT-PLGA NPs rapidly within the acidic environment, whereas the release pattern in physiological pH was slow. Thus, we can assume that the developed NPs formulation would stay in the circulation without releasing the entrapped drug, whereas, if the formulation reaches to the site of action, will release the entrapped drug rapidly to exert its physiological role.

3.4. *Ex vivo* nasal mucosa permeation study {#s0140}
--------------------------------------------

The permeation showed significantly maximum for CS-CTH-PLGA NPs (p \< 0.001) \> CTH PLGA NPs (p \< 0.01) \> CTH-S (Pure) ([Fig. 6](#f0030){ref-type="fig"}A). Maximum permeation was shown by CS-CTH-PLGA NPs i.e. \>82.93 ± 5.91% while 67.98 ± 4.71% for CTH-PLGA-NPs and 20.65 ± 3.01% for CTH-S only ([Fig. 6](#f0030){ref-type="fig"}A). CS has positive charge due to amino group on C2 position that is responsible for interaction to negatively charged membranes of cells therefore, CTH showed enhanced the permeation. Same way, epithelial mucosal cells were also participated to support the mechanism of their tight junctions ([@b0205]). The permeation of pure CTH was very little that represents hydrophilic nature of CTH for excellent justification. Maximum permeability showed with hydrophobic drugs by nasal mucosa or skin reported by [@b0275]. CS-CTH-PLGA-NPs has their surface i.e. lipophilic with \<165.0 nm size NPs easily permeated to biological membrane. At last it is concluded based on above observations: NPs contain lowest size, higher yield (%), maximum % EE with maximum % DL is mainly accountable for maximum permeation of CS-CTH-PLGA-NPs that will offer superior outcome for *in vivo* activity.Fig. 6**\[A\]***Ex vivo* permeation profiles of developed Chitosan-coated-CH--loaded--PLGA--NPs as compared to CTH--loaded--PLGA--NPs and pure CTH-S through goat nasal mucosa. **\[B\]** Cell viability of H1299 cancer cells after 24 h exposure of (A) CTH solution, CS-CTH-PLGA-NPs, and CS-coated PLGA NPs (blank/placebo) nanoformulations. The cell viability was determined by MTT assay. Control consisted of cells treated with 0.1% DMSO (vehicle control, 100% cell viable). Data are expressed as mean ± SD (n = 3).

3.5. Cytotoxicity of CAT and CS-CTH-PLGA NPs {#s0145}
--------------------------------------------

Keeping in view the importance of cytotoxic agents and corresponding cell death assays in cancer drug discovery ([@b0070]), we evaluated the cytotoxic potential of CAT and its nanoformulations (CS-CTH-PLGA-NPs) on NSCLC cell line H1299. The cytotoxicity was examined by MTT \[3-(4, 5- dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide\] assay. The prepared formulations were tested on the human non-small cell lung cancer cell line H1299 was applied to identify the effects of CAT-solution, CS-CTH-PLGA-NPs on cell death and proliferation. CAT-S and CS-CTH-PLGA-NPs has been given a concentration-dependent response at 24 h post-treatment which is and evidence through cell viability or toxicity against H1299 cells ([Fig. 6](#f0030){ref-type="fig"}B). CAT-S and CS-CTH-PLGA-NPs in difference at lesser concentrations have effects on cell death was insignificant but 50.0--100.0 µgml^−1^ higher concentrations have clear difference ([Fig. 6](#f0030){ref-type="fig"}B) followed by cytotoxic effects or cell death CS-CTH-PLGA-NPs being additionally marked and significant (*p* ≤ 0.050) as compared to CAT-S ([Fig. 6](#f0030){ref-type="fig"}B). These results recommended an excellent cytotoxic potential of CAT in the form of CS-CTH-PLGA-NPs. Additionally, CS-CTH-PLGA-NPs showed smaller IC~50~ value i.e. 65.01 µg/mL as compared to CAT-S i.e. 97.14 µg/mL. Here, the results also suggested a higher cytotoxic effect of the CS-CTH-PLGA-NPs as compared to CAT-S. There was no toxicity with CS-PLGA-NPs (Placebo) at any time point or concentration ([Fig. 6](#f0030){ref-type="fig"}B). The cancerous cells (H1299) contained maximum anabolic demands respire mainly through glycolytic i.e. a maximum glucose or nutrient intake, production of lactate, and maximum rate of proliferation as compared to without-cancerous cells. It creates them higher exposure towards CAT-S or CS-CTH-PLGA-NPs. CAT-S or CS-CTH-PLGA-NPs exhibited maximum toxicity to cancer cells (H1299). It can be due to create the obstruction in the uptake of nutrition or membrane transporters inhibition for these cells i.e. usually absent in the non-cancerous cells. CS-CTH-PLGA-NPs have given results a maximum cytotoxic effect as compared to pure-CAT against H1299 cancerous cells. It can be accredited due to lower particle-size and fast uptake of CS-CTH-PLGA-NPs that make easy way to transport via different mechanisms for example passive transport/endocytosis into the cell by lipid bilayer as compared to the healthy cells. On the other hand, a different feature requires an inclusive evaluation at the molecular level to determine the accurate targets of these anticancerous preparations. IC~50~ is the main evaluation end point to determine the concentrations of drug. It means CAT loaded with nanoformulation i.e. CS-CTH-PLGA-NPs showed a greater cytotoxic potential than pure-CAT on the non-small cell lung cancer cells H1299.

3.6. CAT and CS-CTH-PLGA-NPs effects on cellular apoptosis {#s0150}
----------------------------------------------------------

We determined the effects of CAT and their CS-CTH-PLGA-NPs nanoformulation mechanism by the estimation of treatment of cell apoptosis post-CAT through flow cytometry via an annexin V/FITC kit. A significantly induced was observed by cellular apoptosis of CAT (96.68 µg ml^−1^ per 24.0 h) as compared to the without treated with CTH i.e. control group. CS-CTH-PLGA-NPs (65.01 µg ml^−1^ per 24.0 h) was treated to H1299 cells, it was showed a high degree of apoptosis i.e. highly significant (p \< 0.050) as compared to control as well as CAT-S. On the other side, we can see it CAT-S & CS-CTH-PLGA-NPs enhanced necrotic cells number when it compared to control group. Even if later on; the necrotic cells (%) was shown a little reduce than earlier ([Fig. 7](#f0040){ref-type="fig"}). Additionally, we have also observed CS-CTH-PLGA-NPs (76.7%)-treated group significantly higher (p \< 0.05) than CAT-S (51.9%) based on results of early and late apoptotic cells. It has been suggested a strong apoptosis was induced with CS-CTH-PLGA-NPs ([Fig. 7](#f0040){ref-type="fig"}).Fig. 7Quantitative data for induction of apoptotic cell death by the (A) control group (untreated H1299 cells), (B) H1299 cells treated by CTH-solution and (C) CS-CTH-PLGA-NPs. Bar graph analysis showing higher total apoptotic cell death (early + late apoptosis) induced by CS-CTH-PLGA-NPs treatment compared to CTH-solution. Data are expressed as mean ± SD (n = 3). The data were analysed using one-way ANOVA followed by Turkey's post hoc test. The percentage of apoptotic cells in each group was compared with the control group; p \< 0.05 indicates a significant difference.

We evaluated prepared nano-formulation of catechin hydrate to assess whether this nano-formulation enhances its anti-tumor potential using NSCLC cell line H1299. To this end we found that CS-CTH-PLGA-NPs treated cells not only proved more cytotoxic (compared to CAT-alone) to the cancerous cells but also induced apoptosis in NSCLC cell line H1299. The effect was evident by increased percentage % of apoptotic cells in CS-CTH-PLGA-NPs group compared to both CAT-only and control treated cells.

3.7. Bioanalysis by UHPLC/MS/MS {#s0155}
-------------------------------

CTH and IS MS and MS/MS scans were shown [Fig. 8](#f0045){ref-type="fig"} and [Fig. 9](#f0050){ref-type="fig"}. All various matrixes chromatograms showed in [Fig. 10](#f0055){ref-type="fig"} in which **\[A & B\]**, Extracted plasma and lungs homogenate (LH) without the CTH & with CTH **\[C & D\]**, extracted plasma & LH of CTH followed by **\[E & F\]** extracted plasma & LH of Quercetin. Mean recovery of CTH from LH and plasma (n = 6) was showed \>79.68%. All observed matrixes of CTH exhibited a very good linearity (1.0 to 1000.0 ng ml^−1^) i.e. r^2^ \> 0.997. 0.871 & 1.0 ng ml^−1^ was found the LOD and LOQ. The selectivity of all optimized-chromatograms for various matrixes of CTH has been proved. %CV (2.14--3.33% and 2.23--3.17%) was found whereas % accuracy (92.01--99.31% and 93.25--99.31%) exhibited for LH and PL of all QCs in [Table 2](#t0010){ref-type="table"}. Various stability of storage parameters (long-term, bench-top, freeze thaw, and post-processing) for all types of quality control samples were presented in [Table 3](#t0015){ref-type="table"} (US--[@b0325], [@b0025], [@b0120]).Fig. 8Mass spectrum of (A) Catechin Hydrate (CTH) parent ion (protonated precursor \[M−H\]^--^ ions at *m*/*z* 289.21) and (B) Catechin Hydrate (CTH) product ion (major fragmented product ion at *m*/*z* 109.21) showing fragmentation transitions.Fig. 9Mass spectrum of, (A) Quercetin (IS) precursor ion (protonated precursor \[M−H\]^--^ ions at *m*/*z* 301.21 and (B) IS product ion (major fragmented product ions at *m*/*z* 151.21) showing fragmentation transitions.Fig. 10Typical chromatograms of Extracted blank plasma **\[A\]**, Extracted blank lungs homogenate **\[B\]**, Plasma extracted Catechin Hydrate (CH) **\[C\]**, Extracted lungs homogenate Catechin Hydrate (CH) **\[D\]**, Plasma Extracted Quercetin (IS) **\[E\]**, and Extracted lungs homogenate Quercetin (IS) **\[F\]**.Table 2Validation: Precision and Accuracy Data for Catechin Hydrate in Lungs Homogenate and Plasma.BiomatrixQuality Controls SamplesTheoretical Concentration (ng mL^−1^) or (ng g^−1^)Intra-batch precisionInter-batch precisionRecovery^c^ (%)Observed Concentration (ng mL^−1^) or (ng g^−1^) ± S.D.Accuracy^a^ (%)Precision^b^ (%C.V.)Observed Concentration (ng mL^−1^) or (ng g^−1^) ± S.D.Accuracy^a^ (%)Precision^b^ (%C.V.)Lungs HomogenateLOQQC1.010.98 ± 0.02197.032.140.96 ± 0.02595.052.6080.01LQC2.912.89 ± 0.09699.313.322.88 ± 0.09698.973.3379.68MQC420.0392.11 ± 9.6093.362.45386.45 ± 8.8692.012.2982.61HQC805.0795.64 ± 18.7498.842.36783.64 ± 17.6497.352.2579.94  PlasmaLOQQC1.010.97 ± 0.02896.042.890.96 ± 0.02895.052.9280.36LQC2.912.89 ± 0.08699.312.982.87 ± 0.09198.633.1779.94MQC420.0394.54 ± 10.0193.942.54391.64 ± 9.9493.252.5483.02HQC805.0792.16 ± 17.6498.402.23785.38 ± 18.6697.562.3880.39[^2]Table 3Validation: Stability Data for Catechin Hydrate in Lungs Homogenate and Plasma.Exposure conditionLQC (2.91 ng/mL or ng g^−1^)MQC(420.00 ng/mL or ng g^−1^)HQC (805.00 ng/mL or ng g^−1^)Lungs HomogenatePlasmaLungs HomogenatePlasmaLungs HomogenatePlasma**Long term stability; recovery (ng) after storage (−80.0 °C)**Previous day2.88 ± 0.072.86 ± 0.03405.24 ± 11.02406.57 ± 10.32799.36 ± 19.21800.34 ± 18.6130th Day2.81 ± 0.06 (97.57%)2.79 ± 0.04 (97.55%)379.91 ± 910.31 (93.75%)381.61 ± 9.61 (93.86%)788.21 ± 18.22 (98.61%)787.54 ± 17.36 (98.40%)  **Freeze--thaw stress; recovery (ng) after freeze--thaw cycles (−80.0 °C to 25.0 °C)**Pre-Cycle2.89 ± 0.052.90 ± 0.03406.01 ± 9.33406.34 ± 8.55801.15 ± 21.61800.31 ± 20.36First Cycle2.78 ± 0.06 (96.19%)2.80 ± 0.04 (96.55%)391.31 ± 9.22 (96.38%)389.06 ± 9.06 (95.75%)791.31 ± 20.14 (98.77%)789.21 ± 19.47 (98.61%)Second Cycle2.70 ± 0.05 (93.43%)2.71 ± 0.03 (93.45%)379.64 ± 8.17 (93.51)371.69 ± 8.11 (91.47%)779.64 ± 19.61 (97.32%)778.95 ± 20.14 (97.33%)Third Cycle2.61 ± 0.06 (90.31%)2.59 ± 0.05 (89.31%)361.24 ± 8.07 (88.97%)366.17 ± 9.03 (90.11%)770.06 ± 20.14 (96.12%)771.28 ± 21.34 (96.37%)  **Bench top stability; recovery (ng) at room temperature (25.0 °C)**0 hr2.88 ± 0.042.85 ± 0.03407.13 ± 8.61404.34 ± 9.06799.97 ± 21.14801.21 ± 21.6724 hr2.72 ± 0.04 (94.44%)2.73 ± 0.04 (95.79%)384.61 ± 9.18 (94.47%)389.43 ± 9.63 (96.31%)788.24 ± 19.61 (98.53%)783.64 ± 20.34 (97.81%)**Post processing stability; recovery (ng) after storage in auto sampler (4.0 °C)**0 hr2.89 ± 0.052.87 ± 0.03405.18 ± 8.34406.11 ± 10.24800.11 ± 20.36798.24 ± 22.064 hr2.79 ± 0.04 (96.54%)2.75 ± 0.06 (95.82%)381.64 ± 8.21 (94.19%)391.34 ± 9.61 (96.36%)790.32 ± 19.64 (98.78%)788.36 ± 21.34 (98.76%)[^3]

3.8. Pulmonokinetics evaluation {#s0160}
-------------------------------

The study reports for the first time, in-depth and detailed PKs for CS-CTH-PLGA-NPs where the NPs were administered via the major routes of oral, i.v. and intranasal in order to follow the *in vivo* fate for developed NPs. The deposition of NPs in lungs and its engulfment is presented in [Fig. 11](#f0060){ref-type="fig"} and [Table 4](#t0020){ref-type="table"}. A C~max~ (maximum concentration of drug) for NPs in lungs was observed at 2.00 h \[668.24 ± 29.66 ng/g\] (i.n.; p \< 0.001) \>at 2.00 h \[469.31 ± 32.96 ng/g\] (i.v.; p \< 0.01) \>at 2.00 h \[208.76 ± 17.01 ng/g\] (oral). Lungs concentration of CAT was highest by intranasal route for CS-CTH-PLGA-NPs ([Fig. 11](#f0060){ref-type="fig"}, [Table 4](#t0020){ref-type="table"}). Similarly, CS-CTH-PLGA-NPs have been showed enhanced the bioavailability as compared to CTH--S with the help of statistical evaluation for i.n. delivery of CAT. This is a very apparent observation via nose to lungs targeted potential ([@b0225], [@b0105], [@b0340], [@b0170]).Fig. 11Pulmonary Pharmacokinetic Parameters Study of Catechin Hydrate in wistar rats after 10 mg/kg single dose of CS--CTH--PLGA--NPs (intravenous), CS--CTH--PLGA--NPs (Oral), and CS--CTH--PLGA--NPs (Intranasal). Significantly high AUC was achieved with CS--BUD--PLGA--NPs (Intranasal) (p \< 0.001, mean ± SD, n = 6).Table 4Pulmonary Pharmacokinetic parameters of catechin hydrate after single dose (10 mg/kg body weight) of CS-coated-CTH-loaded-PLGA-NPs given by different routes (mean ± SD n = 6).ParametersCS- CTH-PLGA-NPs (IV)CS- CTH-PLGA-NPs (Oral)CS- CTH-PLGA-NPs (Intranasal)Cmax (ng/ml or ng/g)469.31 ± 32.96\*\*208.76 ± 17.01668.24 ± 29.66\*\*\*Tmax (h)2.002.002.00AUC~0-t~ (min ng/ml) or min ng/g)6208.00 ± 89.67\*\*2223.77 ± 42.0811370.02 ± 191.05\*\*\*t~1/2~ (h)26.4710.8291.16K~e~ (h^−1^)0.026190.064080.00760AUC~0-∞~ (min ng/ml) or min ng/g)10628.91 ± 153.0.78\*\*2720.50 ± 83.9157567.74 ± 212.15\*\*\*[^4]

3.9. *In vivo* Histopathological examination of CS-CTH-PLGA-NPs toxicity {#s0165}
------------------------------------------------------------------------

The histological micrographs of lung specimens collected from rat's post seven-days of exposure to 0.90% saline and treated with CS-CTH-PLGA-NPs by intranasal are depicted in [Fig. 12](#f0065){ref-type="fig"}. There was no apparent histopathologic alteration in the lungs tissues ([Fig. 12](#f0065){ref-type="fig"}B) as compared to Normal Saline treated (control group, [Fig. 12](#f0065){ref-type="fig"}A). CS-CTH-PLGA-NPs did not cause any toxicity. These results indicate that CS-CTH-PLGA-NPs are safe and exhibited no obvious toxic effects on the rat's lungs. Exposure of above mentioned particles at mentioned dose does not produce any mortality and also and no abnormal findings in the treated rats with CS-CTH-PLGA-NPs were observed ([@b0210], [@b0130], [@b0050]).Fig. 12*In Vivo* Safety of CS--coated--CTH--loaded--PLGA--NPs: Histopathological evaluation of rat tissues: Normal Saline **(A),** and treated with CS--CTH--PLGA--NPs **(B)** seven days after exposure. The photomicrographs do not shown any evidence of toxicity from the CS-CTH-PLGA-NPs and were no apparent histopathologic changes in the lungs tissues ([Fig. 12](#f0065){ref-type="fig"}B) as compared to Normal Saline treated (control group, [Fig. 12](#f0065){ref-type="fig"}A) (n = 3, Scale = 100 μm).

4. Conclusion {#s0170}
=============

A solvent evaporation (double emulsion) was used to formulate CS-CTH-PLGA-NPs and their optimization was evaluated by low PDI, smaller size of particles, greater EE with high DL and spherical shape. CAT-release was optimized successfully based on a sustained and control release form followed by successfully delivered to lungs with extended retention from nose-to-lungs with passed up hepatic first pass metabolism and also greater nasal permeation upto 24-h for lungs cancer targeting. A +ve zeta potential of the CS coated NPs support binding of the nanocarrier to the cancer cells to exert enhanced cytotoxic potential of the formulation with superior apoptotic potential and cell cycle arrest when compared with CAT alone, CS-CTH-PLGA-NPs exhibited greater apoptotic cell death and cytotoxic in the H1299 cell line. A UPLC-MS/MS method was optimized and validated successfully for the application on pulmokinetics studies of optimized-CS-CTH-PLGA-NPs. At the end, safety of the optimized nanoparticles has been established on the basis of the above results at the time of lungs toxicity studies. At last in this study, CS-CTH-PLGA-NPs have been successfully developed and it can be effectively use as a novel, non-invasive, safe, and effective treatment for lungs targeting in the treatment of lung cancer.
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[^1]: Results expressed as mean ± SD (n = 3). SD: standard deviation; NA: not applicable; NPs: nanoparticles. CTH: Catechin Hydrate, CS: chitosan.

[^2]: Values (Mean ± SD) are derived from 6 replicates: ^a^Accuracy (%) = Mean value of \[(mean observed concentration)/(theoretical concentration)\] × 100; ^b^Precision (%): Coefficient of variance (percentage) = standard deviation divided by mean concentration found × 100; ^c^Recovery (%) = Mean value of (peak height (mV) obtained from extracted biological sample)/(peak height (mV) obtained from aqueous sample) × 100.

[^3]: Values (Mean ± SD) are derived from six replicates. Figures in parenthesis represent analyte concentration (%) relative to time zero. Theoretical contents; LQC: 2.91 ng mL^−1^; MQC: 420.0 ng mL^−1^; and HQC: 805.0 ng mL^−1^.

[^4]: AUC~0--t~, Area under the lungs concentration to time curve; AUC~0-∞~, Area under the plasma concentration to infinite time curve; Cmax, maximum lungs concentration at time t; t~1/2~, mean elimination half-life; and Ke, Elimination Rate Constant. Data are represented as mean ± SD (n = 3). Significantly high AUC and Cmax were achieved with CS--CTH--PLGA--NPs (Intranasal) \*\*\*(p \< 0.001), followed by CS-CTH-PLGA-NPs (IV) \*\*(p \< 0.01) mean ± SD, n = 6).
